Synthesis, molecular structure and reactivity of 5-methylidene-1,2,3,5- tetrahydroimidazo[2,1-b]quinazolines

Article abstract of DOI:10.3390/90300086

Synthesis of novel 5-methylidene-1,2,3,5-tetrahydro[2,1-b]-quinazoline derivatives 2-4 with potential biological activities mediated by α-adrenergic and/or imidazoline receptors was performed by reacting 2-chloro-4,5-dihydroimidazole (1) with the corresponding 2-aminoacetophenones. Compound 2, which incorporates an enamine moiety, underwent a 1,3-dipolar cycloaddition reaction with the appropriate nitrones 5-9 to give 1,2,3,5-tetrahydro-imidazo[2,1-b]quinazolin-5,5′-spiro-2′, 3′-diphenylisoxazolidines 10-14. Reactions of the title compounds 2 and 4 with dimethyl acetylenedicarboxylate (DMAD) afforded dimethyl 2-(2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidenemethyl)but-2-enedioates 15, 16. Imidazo[2,1-b]quinazoline 2 was further treated with acetyl chloride, benzoyl chloride and mesyl chloride to give the 1-substituted derivatives 17, 18 and 19, respectively. The structures of all new compounds obtained were confirmed by elemental analysis and spectral data (IR, ¹H- and ¹³C-NMR) as well as X-ray crystallographic analysis of 3 and 18.

Full text of DOI:10.3390/90300086

Molecules 2004, 9, 86-101
molecules
ISSN 1420-3049
http://www.mdpi.org
Synthesis, Molecular Structure and Reactivity of
5-Methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines
Anita Kornicka 1, Franciszek Sączewski 1,* and Maria Gdaniec 2
1
Department of Chemical Technology of Drugs, Medical University of Gdańsk, 107 Gen. J. Hallera
Str., 80-416 Gdańsk, Poland.
Faculty of Chemistry, A. Mickiewicz University, 60-780 Poznań, Poland
2
* Author to whom correspondence should be addressed. E-mail: saczew@sanus.amg.gda.pl; Tel.
(+48)-58-3493250, Fax (+48)-58-3493257
Received: 21 January 2004 / Accepted: 6 February 2004 / Published: 28 February 2004
Abstract – Synthesis of novel 5-methylidene-1,2,3,5-tetrahydro[2,1-b]-quinazoline
derivatives 2-4 with potential biological activities mediated by α-adrenergic and/or
imidazoline receptors was performed by reacting 2-chloro-4,5-dihydroimidazole (1) with
the corresponding 2-aminoacetophenones. Compound 2, which incorporates an enamine
moiety, underwent a 1,3-dipolar cycloaddition reaction with the appropriate nitrones 5-9
to give 1,2,3,5-tetrahydro-imidazo[2,1-b]quinazolin-5,5'-spiro-2',3'-diphenylisoxazol-
idines 10-14. Reactions of the title compounds 2 and 4 with dimethyl acetylene-
dicarboxylate (DMAD) afforded dimethyl 2-(2,3-dihydroimidazo[2,1-b]quinazolin-
5(1H)-ylidenemethyl)but-2-enedioates 15, 16. Imidazo[2,1-b]quinazoline 2 was further
treated with acetyl chloride, benzoyl chloride and mesyl chloride to give the 1-substituted
derivatives 17, 18 and 19, respectively. The structures of all new compounds obtained
were confirmed by elemental analysis and spectral data (IR, 1H- and 13C-NMR) as well as
X-ray crystallographic analysis of 3 and 18.
Keywords: 5-Methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines, 1,3-dipolar
cycloaddition, alkylation, acylation, X-ray structure analysis.

Molecules 2004, 9
87
Introduction
The well known aryliminoimidazolidines such as clonidine and moxonidine exhibit
antihypertensive activity mediated by α-adrenergic and/or imidazoline receptors [1,2]. These
compounds possess several rotational degrees of freedom and, therefore, offer opportunities for
preparation of restricted analogs.
Previously, it was found that interconnecting the imidazoline and phenyl ring, as achieved in 2,3-
dihydroimidazo[1,2-a]benzimidazole (A) or 1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (B) (Figure
1), afforded agents capable of lowering the blood pressure of experimental animals [3, 4]. On the other
hand, we have recently found that certain 2,3,5,6-tetrahydroimidazo[2,1-b][1,3,5]benzotriazepines of
type C exhibit vasocontractile activity in isolated rabbit aortic rings, which is mediated by KATP
-
dependant channels [5]. The present study was aimed at synthesis, structural elucidation and reactivity
of novel 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines, depicted in Figure 1 as D.
Figure 1.
H
H
N
R
R
HN
N
N
N
N
N
H
N
N
H
N
H
N
N
H
N
C
A
B
D
Results and Discussion
As outlined in Scheme 1, the title 5-methy1idene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines 2
and 4 were obtained by reacting equimolar amounts of 2-chloro-4,5-dihydroimidazole (1) with the
appropriate 2-aminoacetophenone in dichloromethane at ambient temperature. The reaction apparently
proceeds via the intermediacy of the formed cyclic hemiaminal of type E, which loses a water
molecule with the formation of an enamine moiety. However, when compound 1 (1 equiv) was treated
with 2-aminoacetophenone (0.5 equiv) the reaction led to the formation of a mixture of two products
which could be separated by fractional crystallization to afford 1-(4,5-dihydroimidazol-2-yl)-5-methy-
lidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (3) and the expected compound 2 (Scheme 1).
The structures of the compounds 2, 3 and 4 were confirmed by elemental analyses as well as IR
and NMR spectroscopic data. For example, the 1H NMR spectrum of 2 showed a multiplet in the range
of δ 3.59-3.68 originating from CH2-CH2 grouping of the imidazoline ring. Two distinct singlets at δ
3.71 and δ 4.51 were assigned to the nonequivalent olefinic Cβ-H protons.

Molecules 2004, 9
88
Scheme 1.
CH3
N
HO
R1
R2
(i)
Cl
HN
N
- H2O
N
H
N
Cl
H
1
E
H
H
H
H
N
R1
N
N
1
Cl
R1 = R2 = H
R2
N
N
N
H
H
NH
NH
(ii, iv)
H
H
N
H
H
N
H
H
N
R1
R1
R2
R2
N
N
N
H
N
N
N
H
N
NH
2: R1 = R2 = H
3
2A
4A
4: R1 = R2 = OCH3
(i) 2-Amino-4-R1-5-R2-acetophenone / CH2Cl2 / r.t.; (ii) 10% NaOH / H2O; (iv) fractional
crystallization.
13
The fusion of the two ring systems was confirmed by the presence in the C-NMR spectrum of
two signals at δ 140.17 and δ 154.11, attributable to the C-5 and C=N carbon atoms of the
1
imidazoquinazoline moiety, respectively. On the other hand, a characteristic feature of the H-NMR
spectrum of the 1-substituted derivative 3 is the presence of two distinct multiplets in the range of δ
3.66-3.71 and δ 4.07-4.09 integrating to six and two protons, respectively, attributable to the two CH2-
CH2 groupings of the imidazoline rings. In 13C-NMR spectrum, two broad carbon resonances were
observed at δ 45.66 and δ 50.92, attributable to C-4′ and C-5′ of the 2-substituted imidazoline ring, and
a signal at δ 148.75, which in the HSQC (heteronuclear single quantum coherence) spectrum did not
1
1
correlate to any H resonances. Analysis of the long-range H-13C coupling pattern obtained from the
HMBC (heteronuclear multiple bond coherence) experiment allowed us to assign this signal to the C-2′
carbon atom of the imidazoline ring. The structure of 3 was then confirmed unambiguously by X-ray
crystallographic analysis (Figure 2).

Molecules 2004, 9
Figure 2. ORTEP drawing showing the asymmetric part of the unit cell of 3 and atom
89
labelling. Hydrogen bonds are shown with dashed lines. Displacement ellipsoids are
drawn at 50% probability level.
The condensed tricyclic system of 3 is virtually planar with the imidazoline substituent
aproximately in its plane. This conformation is stabilized by an intramolecular hydrogen bond N18-
H⋅⋅⋅N1 (H18A⋅⋅⋅N1A 2.10 Å, <N18A-H18A⋅⋅⋅N1A 126º; H18A⋅⋅⋅N1A 2.08 Å, <N18A-H18A⋅⋅⋅N1A
126º). Whereas bonds C2-N1 and C14-N15 show considerable double-bond character [1.287(3) and
1.277(3) Å, respectively, for the molecule A; 1.280(3) and 1.277(3) Å, respectively, for the molecule
B], the bonds C9-N1, C4-N3, N3-C2, C2-N11, N11-C14 and C14-N18 [bond lengths 1.337(3)-
1.400(3) Å] are intermediate between single and double bonds. The C4-C18 bond of 1.334(3) Å is
longer than the double bond in a disubstituted vinyl group (1.321 Å) [6] indicating that it is conjugated
with the guanidine fragment and the benzene ring. The nitrogen atoms N3 and N11 show sp2
hybridization, the maximum displacement of the N atom from the plane of its substituents being 0.037
Å.
Scheme 2.
R3
H
O
N
O
N
H
H
N
R3
H
H
C
H
R1
R2
N
5 - 9
(i)
N
N
H
N
N
H
2, 4
10 - 14
Compd
R3
H
(ii)
5, 10
6, 11
7, 12
8, 13
9, 14
4-CH3
4-Cl
O
O
H
3-Cl
CH3
CH3
C
O
O
4-OCH3
H
C
R1
R2
N
N
N
H
15: R1 = R2 = H
(i) THF / 7h / reflux; (ii) DMAD / CH3OH / rt.
16: R1 = R2 = OCH3

Molecules 2004, 9
90
Enamines are known to act as 1,3-dipolarophiles [8,9] and the 1,3-dipolar cycloaddition of nitrones
to enamines resulting in the formation of isoxazolidine derivatives is well established [10-12]. Thus,
the 1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline 2 was subjected to the reaction with nitrones. Upon
treatment of 2 with an excess of the appropriate N-(benzylidene)aniline N-oxide 5-9 in anhydrous THF
under reflux, the desired 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(3″- or 4″-
R3-phenyl)isoxazolidines 10-14 were obtained (Scheme 2). For the structural analysis of the
compounds 10-14 a complete assignment of all protons was made using HSQC and HMBC spectra.
For example, in the 1H-NMR spectrum of 10 the AMX system was observed due to CH2-CH grouping
of the isoxazoline ring formed: δ 3.03 (dd, 1H, part A of AMX system, JA,M = 13.67 Hz, JA,X = 10.25
Hz); δ 3.42 – 3.47 (dd, 1H, part M of AMX system); δ 4.88, dd, 1H, part X of AMX system, JAX
=
10.25 Hz, JMX = 8.18 Hz). In the HMBC spectrum the protons C4'-H correlated to the carbon
resonances at δ 71.93 (C3′) and δ 91.11 (C5-O) and the C3′-H resonance showed a long-range
correlation to the carbon signal at δ 51.46 (C4′). Hence, the results of NMR experiments supported the
presence of 5,5’-spiro-isoxazolidine ring.
Next, we examined the reaction of 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines 2 and 4 with
dimethyl acetylenedicarboxylate (DMAD). It is well known, that the reactions of enamines with
DMAD, depending on solvent and temperature, afford either the cycloaddition [13, 14] or Michael
addition [13, 15] products. To identify reactive sites both at the alkene and nitrogen atom incorporated
into guanidine moiety, the electronic structure of 2 was studied using ab initio 6-31G** calculations
[7]. Reactive sites will correspond to regions where either the highest-occupied molecular orbital
(orbital-controlled reactions) or negative charge (electrostatically-controlled reactions) is large. As
shown in Scheme 1, the imidazoquinazoline 2 can exist in two possible tautomeric forms, the N1-H
tautomer (2) or the N10-H tautomer (2A). Calculations of the corresponding energies indicate that 2 is
more stable than 2A by 5.1 kcal/mol (Figure 3).
Figure 3. Calculated [7] natural charges (plain), charges from Mulliken population
analysis (italic) and atomic charges from electrostatic potential (underlined) for selected
atoms of 2 and 2A.
Cα
0.25
0.50
0.35
N4 - 0.55
- 0.85
N4 - 0.56
- 0.84
Cα
0.24
0.50
0.41
H
H
H
H
Cβ
Cα
Cβ
Cα
- 0.26
- 0.30
N4
N4
- 0.55
- 0.42
- 0.69
- 0.53
- 0.41
- 0.70
Cβ
Cβ
N10 N1
N10 N1
H
H
N10 - 0.67
- 0.73
N1 - 0.72
- 0.74
N1 - 0.66
- 0.55
2
2A
N10 - 0.69
- 0.88
- 0.86
- 0.74
- 0.83
- 0.76
E = - 586.3258768 a.u.
E = - 586.3176608 a.u.
E = 5.1 kcal / mol

Molecules 2004, 9
91
Figure 4. Absolute values of HOMO (left) and electrostatic potential (right) mapped in
color [7] onto the surface of electron density of 2.
The magnitudes of the calculated charges at N1, N4 and N10 suggest that the electrostatically-
controlled reactions of 2 and 2A should give rise to the formation of either the N10- or N1-substituted
products. On the other hand, the HOMO (0.0190 a.u.) have the highest contribution for Cβ carbon
atom of enamine moiety which should be involved in the orbital-controlled reactions with electrophiles
(Figure 4). Treatment of 2 and 4 with DMAD in methanol at room temperature gave rise to the
formation of the Michael addition products dimethyl 2-(2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-
ylidenemethyl)but-2-enedioates (15 and 16) (Scheme 2). Apparently, the orbital-controlled reaction
1
13
took place exclusively since no N-alkenylation was observed. In the H- and C-NMR spectra of 15
the presence of two methoxycarbonyl groups was confirmed by the resonances at δH 3.37 and 3.76
(OCH3 groups) and δC 51.64 and 52.70 (OCH3 groups), as well as δC 167.41 and 168.77 (C=O groups).
The N1-H proton appeared as a broad singlet at δ 7.58 ppm.
R
Scheme 3.
H
H
N
H
O
N
N
(i)
N
N
2
N
H
R
O
17: R = CH 3
18: R = C6H5
(ii)
CH3
CH3
S
O
O
S
H
H
O
O
N
N
(i) DMAD / CH3OH / rt;
(ii) MsCl / pyridine / 0 ºC – rt.
+
N
N
S
N
N
S
O
O
H3C
H3C
O
O
19 (E)
19 (Z)

Molecules 2004, 9
92
Compound 2 was then subjected to reaction with electrophilic acetyl chloride and benzoyl chloride
in pyridine at ambient temperature to afford the corresponding N1-substituted enaminones 17 and 18,
respectively (Scheme 3). It is well known that enaminones can exist in the four possible conformations
depicted in Figure 5 due to restricted rotation around the C=C double and the C−C=O single bonds
[16-22].
Figure 5.
R1
O
R1
O
H
H
H
H
N
R1
R
R1
O
R
O
R
R
R2
R2
R2
R2
N
R
N
R
N
R
R
ZZ
EZ
ZE
EE
Analysis of the 1H-NMR spectra of compound 17 run in CDCl3 revealed doubled signals indicating
the presence of a mixture of ZZ and EZ isomers (Figure 6). The olefinic Cβ-H proton appears at δ 5.22
for 17 (EZ), and at δ 6.13 for 17 (ZZ). Deshielding of the olefinic proton of ZZ isomer results from its
relative proximity to the benzene ring. Furthermore, the aromatic proton C6-H of the EZ isomer (δ
9.03) is downfield of that of the ZZ isomer (δ 7.84) by 1.19 ppm, while signals of other protons are not
duplicated.
Figure 6.
NOE
CH
CH
3
3
H
H
N
NOE
O
O
N
N
N
N
N
CH
O
CH
O
3
3
17 (ZZ)
17 (EZ)
E = 1.1 kcal / mol
E= - 889.87009960 a.u.
dipole moment = 2.89 Debye
E = - 889.8683975 a.u.
dipole moment = 7.54 Debye
CH
3
O
N
O
N
N
CH
3
F

Molecules 2004, 9
93
As shown in Figure 6, the ROESY spectrum of 17 displayed intense NOE cross peaks between the
resonances of Cβ-H and both CH3 and C6-H for ZZ isomer, whereas for isomer EZ the corresponding
NOE effect was observed between Cβ-H and CH3 group only. Based on the relative intensities of
signals observed in 1H NMR spectrum we conclude that in CDCl3 the compound 17 exists in form of a
mixture of two isomers ZZ and EZ in ratio 3.3 : 1.
Quantum chemical calculations [7] indicate that the EZ and ZZ isomers of 17 differ in energy by
only 1.1 kcal/mol. Based upon their calculated dipole moments, EZ (µ = 7.54 D) would be predicted to
predominate over ZZ (µ = 2.89 D) in polar solvents. Indeed, an inspection of the 1H NMR spectrum of
17 run in DMSO-d6 revealed a change of the ZZ/EZ isomer ratio to 1 : 1.1 (see Experimental section).
Hence, these data postulate that the isomerism observed is due to a restricted rotation around the C=C
double bond and the interconversion between ZZ and EZ isomers is possible via a zwitterionic
intermediate of type F (Figure 6).
It should be pointed out that 2-(1-benzoyl-2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidene)-1-
phenyl-ethen-1-one (18) exists both in solution and solid phase as a single ZZ isomer, which was
confirmed by NMR spectroscopy and X-ray crystallographic analysis (Figure 7).
Figure 7. ORTEP drawing of molecule 18 with atom labelling. Displacement ellipsoids
were draw at 50% probability level.
The tricyclic system of 18 is less planar than in 3 (cf. Figure 2) due to the steric hindrance caused
by introduction of the benzoyl substituent at C14. The release of this strain is accomplished by a twist
about the formally double C4-C14 and partially double C14-C15 bonds by 21.6º and 31.3º,
respectively. In effect the carbonyl O16 is at a distance of 2.24 Å from one of the imidazolidine C13
hydrogen atoms, i.e. at a distance ca. 0.4 Å shorter than the sum of appropriate van der Waals radii
[23]. The formally double bond C4-C14 which is conjugated not only with the quinazoline moiety like
in 3 but also with the benzoyl group is significantly longer and equals to 1.367(3) Å. The tertiary

Molecules 2004, 9
94
amide group is strongly non-planar with atoms C12 and C2 deviating from the plane of C25, C23, O24
and N11 by –0.224 and 0.539 Å, respectively. Contrary to 3, the nitrogen atoms N3 and N11 show
hybridization intermediate between sp2 and sp3with the displacement of the N atoms from the plane of
their substituents equal to 0.099 and 0.146 Å, respectively.
Finally, we have also performed the reaction of 2 with methanesulfonyl chloride (MsCl). The
reaction proceeded smoothly in pyridine at ambient temperature and furnished 1-mesyl derivative 19
(Scheme 3), which, as evidenced by its 1H-NMR spectrum run in DMSO-d6, exists as a mixture of ZZ
and EE isomers in a 1 : 9 ratio, respectively.
Conclusions
We have found that 2-chloro-4,5-dihydroimidazole (1) reacts with 2-aminoacetophenones to give
tricyclic 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolines (2-4) with potential circulatory
activity. These compounds undergo facile reactions characteristic of enamine functionality such as 1,3-
dipolar cycloaddition, Michael addition and electrophilic alkenylation at the Cβ carbon atom and/or N1
nitrogen atom.
Acknowledgements
We thank the State Committee for Scientific Research (Grant KBN No.6 PO5F 03821) for
financial support.
Experimental
General
Melting points (mp) were determined on a Büchi 535 apparatus and are uncorrected. IR spectra
1
(KBr pellets) were measured on a Perkin Elmer 1600 FTIR spectrophotometer. H-NMR and
13C-NMR were recorded on a Varian Gemini 200 or Varian Unity 500 spectrometer and chemical
shifts (δ) are expressed in ppm relative to internal tetramethylsilane. 2D NMR experiments were
carried out on a Varian Unity Plus 500 spectrometer. Mass spectra were recorded on a Finnigan MAT
95 spectrometer at 70 eV. The starting 2-chloro-4,5-dihydroimidazole (1) and N-oxides N-(3- or 4-R3-
benzylidene)aniline (5-9) were prepared according to procedures described previously [24, 25].
5-Methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (2) and 1-(4,5-Dihydro-1H-imidazol-2-
yl)-5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline hydrate (3).
2-Aminoacetophenone (1.66 g, 12.3 mmol) was added to a solution of 1 (2.5 g, 24 mmol) in
CH2Cl2 (30 mL) and the reaction mixture was stirred at ambient temperature for 17 h. The solid that

Molecules 2004, 9
95
precipitated was collected by filtration, washed with CH2Cl2 (20 mL), dried and dissolved in water (25
mL). To the solution thus obtained 10% aqueous NaOH (10 mL, 25 mmol) was added and the resulting
mixture was stirred for 30 min. The crude product (a mixture of 2 and 3) was filtered off, washed with
water (10 mL), dried and heated in toluene (1:5) under reflux for 5 min. Then, the insoluble material
was separated from the filtrate (denoted as “A” and stored for further work up), washed with hot
toluene (4 mL) and dried to give 2 (0.42 g, 18%). The; mp 194-197°C; IR (KBr) cm-1: 3155, 3110,
1
3060, 3020, 2860, 1655, 1615, 1595, 1560, 1495, 1460, 1440, 1280; H-NMR (200 MHz, DMSO-d6)
δ: 3.59-3.68 (m, 4H, 2CH2), 3.71 (s, 1H, CH), 4.51 (s, 1H, CH), 6.86-6.90 (m, 2H, H-7, -9), 7.13-7.24
13
(m, 2H, H-8 and NH), 7.58 (d, J6,7 = 7.4 Hz, 1H, H-6); C-NMR (200 MHz, DMSO-d6) δ: 39.75,
44.14, 75.60, 118.17, 121.09, 122.91, 123.54, 129.88, 140.17, 145.68, 154.11; Anal. Calcd. for
C11H11N3: C, 71.33; H, 5.98; N, 22.68; Found: C, 71.02; H, 5.69, N, 22.82.
The filtrate “A” was concentrated under reduced pressure. The precipitate thus obtained was
collected by filtration and recrystallized from toluene to give 3 (0.43 g, 13%); mp 118-121°C; IR
(KBr) cm-1: 3320, 3290, 2935, 2860, 1655, 1615, 1600, 1505, 1485, 1460, 1435, 1340, 1280; 1H-NMR
(500 MHz, CDCl3) δ: 3.66-3.71 (m, 6H, 3CH2), 3.72 (d, J = 2.44 Hz, 1H, CH), 4.07-4.09 (m, 2H,
CH2), 4.55 (d, J = 2.44 Hz, 1H, CH), 7.02 (ddd, J7,6 = 7.81 Hz, J7,8 = 7.33 Hz, J7,9 = 1.46 Hz, 1H, H-7),
7.08 (dd, J9,8 = 8.30 Hz, J9,7 = 1.46 Hz, 1H, H-9), 7.24-7.27 (m, 1H, H-8), 7.53 (dd, J6,7 = 7.81 Hz, J6,8
= 1.47 Hz, 1H, H-6), 7.73 (br s, 1H, NH); 13C-NMR (500 MHz, CDCl3) δ: 42.36, 42.72, 45.66, 50.92,
77.90, 119.28, 123.03, 124.10, 125.30, 130.57, 140.05, 142.96, 148.75, 157.60; Anal. Calcd. for
C14H15N5·H2O: C, 61.98; H, 5.57; N, 25.81; Found: C, 61.72; H, 5.32, N, 25.64.
7,8-Dimethoxy-5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (4).
The reaction of 1 (2.5 g, 24 mmol) with 2-amino-4,5-dimethoxyacetophenone (2.40 g, 12.3 mmol)
was carried out according to the procedure described above for 2 and 3. The crude product obtained
was recrystallized from dioxane to give 4 (0.8 g, 33%); mp 185-189°C; IR (KBr) cm-1: 3170, 3115,
3075, 3010, 2880, 2835, 1655, 1625, 1615, 1510, 1490, 1450, 1420, 1270, 1225, 1210; 1H-NMR (500
MHz, DMSO-d6) δ: 3.50-3.53 (m, 2H, CH2), 3.55 (s, 1H, CH), 3.60-3.64 (m, 2H, CH2), 3.71 (s, 3H,
OCH3), 3.72 (s, 3H, OCH3), 4.29 (s, 1H, CH), 6.41 (s, 1H, H-9), 6.88 (1H, br s, NH), 6.99 (1H, s, H-
6); 13C-NMR (500 MHz, DMSO-d6) δ: 39.69, 44.83, 55.90, 56.60, 74.08, 106.45, 107.06, 110.57,
140.87, 141.12, 145.00, 151.59, 154.32; MS (70 eV) m/z: 245 (M+, 100%); Anal. Calcd. for
C13H15N3O2: C, 63.67; H, 6.16, N, 17.13; Found: C, 63.35; H, 5.97, N, 17.01.
General Procedure for the Preparation of 1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-
phenyl-3′-(3′′- or 4′′-R3-phenyl)isoxazolidines (10-14).
A mixture of 2 (0.45 g, 2.4 mmol) and the appropriate N-(3- or 4-R3-benzylidene)-aniline N-oxide
(5-9) (5.3 mmol) in anhydrous THF (15 mL) was refluxed for 7 h, and then, the resulting solution was
allowed to stand overnight before workup according to procedures A or B.

Molecules 2004, 9
96
Procedure A: The precipitate thus obtained was separated by suction, washed successively with
anhydrous THF (6 mL) and anhydrous acetone (10 mL) and dried to give the products 10 and 11,
respectively.
1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′,3′-diphenylisoxazolidine (10). Yield 50%;
mp 173-174°C (dec.); IR (KBr): 3155, 3100, 3060, 2865, 2830, 1660, 1595, 1570, 1475, 1460, 1280
cm-1; 1H-NMR (500 MHz, DMSO-d6) δ: 3.03 (dd, JA,M = 13.67 Hz, JA,X = 10.25 Hz, 1H, HA-4′), 3.35-
3.39 (m, 1H, CH2), 3.42-3.47 (m, 1H, HM-4′), 3.50-3.53 (m, 1H, CH2), 4.09-4.23 (m, 2H, CH2), 4.88
(dd, JX,A = 10.25 Hz, JX,M = 8.18 Hz, 1H, HX-3′), 6.81-6.96 (m, 6H, Ar), 7.10-7.18 (m, 3H, Ar), 7.31-
13
7.43 (m, 3H, 2H aromat. and NH), 7.56-7.61 (m, 3H, Ar); C-NMR (500 MHz, DMSO-d6) δ: 39.54,
44.62, 51.46, 71.93, 91.11, 117.09, 119.57, 121.18, 121.89, 122.74, 124.39, 127.16, 127.76, 127.91,
128.57, 129.02, 129.63, 129.81, 140.33, 146.01, 149.28, 156.67; Anal. Calcd. for C24H22N4O: C,
75.37; H, 5.80; N, 14.65; Found: C, 75.18; H, 5.48; N, 14.19.
1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(4′′-methylphenyl-isoxazolidine
(11). Yield 54%; mp172-173°C (dec.); IR (KBr): 3165, 3050, 3025, 2970, 2920, 2850, 1650, 1595,
1
1490, 1475, 1460, 1280 cm-1; H-NMR (200 MHz, DMSO-d6) δ: 2.31 (s, 3H, CH3), 3.01 (dd, JA,M
=
13.56 Hz, JA,X = 10.34 Hz, 1H, HA-4′), 3.43-3.63 (m, 3H, HM-4′ and CH2), 4.10-4.25 (m, 2H, CH2),
4.83 (dd, JX,A = 10.34 Hz, JX,M = 8.52 Hz, 1H, HX-3′), 6.80-7.01 (m, 6H, Ar), 7.12-7.23 (m, 5H, 4H Ar
and NH), 7.48-7.59 (m, 3H, Ar); Anal. Calcd. for C25H23N4O: C, 75.93; H, 5.86; N, 14.17; Found: C,
76.21; H, 6.11; N, 13.91.
Procedure B: The insoluble side products were filtered off and then the solvent was distilled off under
reduced pressure. The residue was treated with anhydrous acetone (7 mL), and the precipitate thus
obtained was collected by filtration, washed with acetone (5 mL) and dried to give the products 12–14.
1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(4′′-chlorophenyl)isoxazolidine
(12). Yield 58%; mp172-175°C (dec.); IR (KBr): 3160, 3100, 3030, 2870, 1660, 1595, 1570, 1490,
1480, 1460, 1280 cm-1; 1H-NMR (200 MHz, DMSO-d6) δ: 3.01-3.09 (m, 1H, H-4′), 3.45-3.58 (m, 3H,
H-4′ and CH2), 4.11-4.25 (m, 2H, CH2), 4.95-5.00 (m, 1H, H-3′), 6.79-7.23 (m, 9H, Ar), 7.53-7.67 (m,
5H, 4H Ar and NH); Anal. Calcd. for C24H21ClN4O: C, 69.14; H, 5.08; N, 13.44; Found: C, 69.27; H,
4.92; N, 13.59.
1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(3′′-chlorophenyl)isoxazolidine
(13). Yield 67%; mp 158-161°C; IR (KBr): 3160, 3095, 3060, 3025, 2885, 2865, 1660, 1595, 1570,
1
1485, 1475, 1460, 1280 cm-1; H-NMR (200MHz, DMSO-d6) δ: 3.04 (dd, JA,M = 13.56 Hz, JA,X
=
10.34 Hz, 1H, HA-4′), 3.29-3.56 (m, 3H, HM-4′ and CH2), 4.13-4.26 (m, 2H, CH2), 5.00 (dd, J = 10.34
Hz, J = 9.52 Hz, 1H, HX-3′), 6.79-7.01 (m, 5H, Ar), 7.12-7.23 (m, 3H, Ar), 7.39-7.64 (m, 5H, 4H Ar

Molecules 2004, 9
97
and NH); Anal. Calcd. for C24H21ClN4O: C, 69.14; H, 5.08; N, 13.44; Found: C, 68.96; H, 5.16; N,
13.62.
1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolin-5,5′-spiro-2′-phenyl-3′-(4″-methoxyphenyl)isoxazolidine
(14). Yield 68%; mp 158-160°C (dec.); IR (KBr): 3160, 3100, 3030, 2880, 2830, 1650, 1595, 1570,
1510, 1490, 1460, 1285, 1250 cm-1; 1H-NMR (200 MHz, DMSO-d6) δ: 3.04-3.12 (m, 1H, H-4′), 3.40-
3.53 (m, 3H, H-4′ and CH2), 3.78 (s, 3H, OCH3), 4.13-4.22 (m, 2H, CH2), 4.78-4.87 (m, 1H, H-3′),
6.79-7.00 (m, 7H, Ar), 7.01-7.23 (m, 3H, Ar), 7.39 (s, 1H, NH), 7.50-7.66 (m, 3H, Ar); Anal. Calcd.
for C25H24N4O2: C, 72.79; H, 5.86; N, 13.58; Found: C, 72.63; H, 6.11; N, 13.22.
General Procedure for the Preparation of Dimethyl 2-(7-R1-8-R2-2,3-dihydroimidazo[2,1-b]-quinazol-
ine-5(1H)-ylidenemethyl)but-2-enedioates (15, 16).
To a suspension of the appropriate 5-methylidene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazoline (2
or 4) (1.4 mmol) in anhydrous methanol (20 mL) DMAD (0.23 g, 1.6 mmoles) was added. The
resulting mixture was stirred at room temperature for 15 h, and then the crude product (15 or 16) was
separated by suction, washed with methanol (4 mL), dried and purified by crystallization from
anhydrous methanol.
Dimethyl 2-(2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidenemethyl)but-2-enedioate (15). Yield
0.2 g (38%); mp 183-184°C; IR (KBr): 3170, 3115, 3020, 2880, 1715, 1700, 1665, 1600, 1580, 1460,
1
1250, 1180 cm-1; H-NMR (500 MHz, CDCl3) δ: 3.37 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.79-3.82
(m, CH2), 3.99-4.03 (m, CH2), 6.21 (s, 1H, HC=C), 6.29 (d, J = 1.47 Hz, 1H, HC-CO), 6.91-7.00 (m,
2H, H-7, -9), 7.25-7.31 (m, 2H, H-6, -8), 7.58 (br s, 1H, NH); 13C-NMR (500 MHz, CDCl3) δ: 39.76,
45.76, 51.64, 52.70, 93.02, 118.54, 119.18, 121.95, 123.20, 128.09, 131.70, 143.67, 146.16, 146.84,
155.07, 167.41, 168.77; Anal. Calcd. for C17H17N3O4: C, 62.38; H, 5.23; N, 12.84; Found: C, 62.01; H,
5.17; N, 12.60.
Dimethyl
2-(7,8-dimethoxy-2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidenemethyl)-but-2-ene-
dioate (16). Yield 0.31 g (57%); mp 215-216°C (dec.); IR (KBr): 3165, 3110, 3040, 2945, 2890, 2840,
1
1725, 1700, 1660, 1615, 1565, 1440, 1260, 1210, 1180 cm-1; H NMR (200 MHz, CDCl3) δ: 3.43 (s,
3H, OCH3), 3.73-3.81 (m, 5H, CH2 and OCH3), 3.84 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 4.01-4.09 (m,
2H, CH2), 6.16 (s, 1H, HC=C), 6.24 (s, 1H, HC-CO), 6.60 (s, 1H, H-9), 6.77 (s, 1H, H-6); Anal. Calcd.
for C19H21N3O6: C, 58.91; H, 5.46; N, 10.85; Found: C, 58.79; H, 5.28; N, 10.51.
1-(1-Acetyl-2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidene)acetone (17).
To a suspension of 2 (0.53 g, 3 mmol) in pyridine (10 mL) acetyl chloride (0.71 g, 9 mmol) was
added at 0 ºC. After an exothermic reaction had subsided (15 min), the reaction mixture was stirred at

Molecules 2004, 9
98
rt for 6 h. Then, the precipitate was collected by filtration, dried, and treated with water (10 mL). The
mixture thus obtained was made alkaline to pH 9 with 5% aqueous Na2CO3 and filtered off to give the
crude product 17 as a mixture of two isomers (ZZ/EZ) which was purified by crystallization from
DMF. Yield 0.43 g (56%); mp 202-205 °C; Anal. Calcd. for C15H15N3O2: C, 66.90; H, 5.61; N, 15.60;
Found: C, 66.78; H, 5.42; N, 15.62; IR (KBr): 3060, 2920, 1680, 1645, 1635, 1600, 1560, 1520, 1480,
1
1470, 1410, 1380, 1230, 1150 cm-1; H-NMR (500 MHz, CDCl3): ZZ/EZ isomer ratio 3.3:1,
respectively: δ: 2.30 (s, 3H, OCH3), 2.77 (s, 3H, OCH3), 3.85-3.89 (m, 0.92H, CH2CH2 imidaz., EZ
isomer), 4.07-4.20 (m, 3.08H, CH2CH2 imidaz., ZZ isomer), 5.22 (br s, 0.23H, CH, EZ isomer), 6.13
(s, 0.77H, CH, ZZ isomer), 7.22-7.40 (m, 2H, H-7, -9), 7.49-7.57 (m, 1H, H-8), 7.84 (s, 0.77H, H-6,
ZZ isomer), 9.03 (br s, 0.23H, H-6, EZ isomer); ZZ/EZ isomer ratio 1:1.1, respectively: δ: 2.21 (s, 3H,
OCH3), 2.64 (s, 3H, OCH3), 3.93-3.97 (m, 4H, CH2CH2 imidaz.), 5.38 (s, 0.52H, CH, EZ isomer), 6.30
(s, 0.48H, CH, ZZ isomer), 7.20-7.31 (m, 2H, H-7, -9), 7.56 (s, 1H, H-8), 8.05 (s, 0.47H, H-6, ZZ
isomer), 9.11 (s, 0.53H, H-6, EZ isomer).
2-(1-Benzoyl-2,3-dihydroimidazo[2,1-b]quinazolin-5(1H)-ylidene)-1-phenylethen-1-one (18).
Benzoyl chloride (0.98 g, 7 mmol) was added at 0 ºC to a suspension of 2 (0.43 g, 2.3 mmol) in
pyridine (10 mL). After the initial exothermic reaction had subsided (ca. 15 min), the reaction mixture
was stirred at rt for 6 h, and then concentrated to dryness under reduced pressure. The residue was
treated with 5% aqueous Na2CO3 and extracted with methylene chloride (100 mL). The organic phase
was dried over MgSO4 and then the solvent was evaporated under reduced pressure. The dry residue
thus obtained was recrystallized from DMF to give 18 (0.42 g, 47%); mp 207-210°C; IR (KBr): 3060,
1666, 1645, 1620, 1595, 1530, 1470, 1400, 1315, 1220 cm-1; 1H-NMR (500 MHz, CDCl3) δ: 4.24-4.29
(m, 4H, 2CH2), 6.74 (br s, 1H, CH), 6.91 (d, J = 7.81 Hz, 1H, Ar), 7.21-7.24 (m, 1H, Ar), 7.40-7.58
(m, 7H, Ar), 7.71-8.04 (m, 5H, Ar); 13C-NMR (500 MHz, CDCl3) δ: 43.27, 46.90, 91.16, 119.07,
123.77, 125.71, 127.01, 127.58, 128.24, 128.35, 129.01, 131.61, 131.70, 132.68, 134.36, 140.33,
143.72, 146.89, 148.28, 169.37, 186.82; MS (70 eV) m/z 393.1 (M+ 100%); Anal. Calcd. for
C25H19N3O2: C, 76.32; H, 4.87; N, 10.68; Found: C, 76.05; H, 4.61; N, 10.70.
1-Mesyl-5H-5-mesylomethylidene-2,3-dihydroimidazo[2,1-b]quinazoline (19).
To a suspension of 2 (1 g, 5.4 mmol) in pyridine (10 mL) MsCl (1.85 g, 16.2 mmol) was added at 0
ºC. After the exothermic reaction had subsided (15 min), the reaction mixture was stirred at rt for 72 h.
Then, the precipitate was collected by filtration and treated with water (10 mL). The solution thus
obtained was made alkaline to pH 9 with 5% aqueous Na2CO3 and the solid that precipitated was
filtered off to give the crude product 19 as a mixture of two isomers (Z/E) in a ratio 1:9, which was
purified by crystallization from methanol. Yield: 0.7 g (38%); mp 220-221°C (dec.); IR (KBr): 3010,
2920, 1640, 1600, 1565, 1540, 1480, 1420, 1350, 1280, 1260, 1160 cm-1; 1H-NMR (200 MHz, DMSO-
d6) δ: 3.17 (s, 3H, CH3), 3.35 (s, 3H, CH3), 3.90-4.08 (m, 3.6H, CH2CH2 imidaz., E isomer), 4.46-4.62

Molecules 2004, 9
99
(m, 0.4H, CH2CH2 imidaz., Z isomer) 5.55 (s, 0.9H, CH, E isomer), 6.45 (s, 0.1H, CH, Z isomer),
7.32-7.60 (m, 3H, H-7, -8, -9), 7.98 (d, J = 5.35 Hz, 0.1H, H-6, Z isomer), 8.59 (d, J = 5.45 Hz, 0.9H,
H-6, E isomer); Anal. Calcd. for C13H15N3O4S2: C, 45.73; H, 4.40; N, 12.31; Found: C, 45.89; H, 4.26;
N, 12.28.
X-Ray Structure Analysis of Compounds 3 and 18 [26].
Crystal data for C14H15N5·H2O (3): monoclinic, space group P21/c, a = 15.952(1), b = 4.995(1), c =
33.246(1) Å, β = 93.61(1), V = 2643.8(6) Å3, Z = 8, dχ = 1.363 g.cm-3, T = 293 K. Data were collected
for a crystal with dimensions 0.5 x 0.3 x 0.05 mm on a Kuma KM4 diffractometer using graphite
monochromated Cu Kα radiation. Final R indices for 3031 reflections with I>2σ(I) and 368 refined
parameters are: R1 = 0.0457, wR2 = 0.1105 (R1 = 0.0867, wR2 = 0.1270 for all 2102 data).
Crystal data for C25H19N3O2 (18): orthorhombic, space group Pna21, a = 11.6591(11), b =
9.8033(9), c = 17.1225(16) Å, V = 1957.1(3) Å3, Z = 4, dχ = 1.335 g.cm-3, T = 293 K. Data were
collected for a crystal with dimensions 0.5 x 0.5 x 0.5 mm on a Kuma CCD diffractometer using
graphite monochromated Mo Kα radiation. Final R indices for 1879 reflections with I>2σ(I) and 291
refined parameters are: R1 = 0.0376, wR2 = 0.0927 (R1 = 0.0432, wR2 = 0.0969 for all 4437 data).
References and Notes
1.
Ruffolo Jr., R.R.; Bondinell, W.; Hieble, J.P. α- and β-Adrenoceptors: From the Gene to the
Clinic 2. Structure-Activity Relanstioships and Therapeutic Applications. J. Med. Chem. 1995,
38, 3683-3716.
2.
Farsang, C.; Kapocsi, J. Imidazoline Receptors: From Discovery to Antihypertensive Therapy
(facts and doubts). Brain Res. Bull. 1999, 49, 317-33.
3. Jen, T.; Bender, P.; Van Hoeven, H.; Dienel B.; Loev, B. Amidines 4. Synthesis of Tricyclic
Guanidines Related to 1,2,3,5-Tetrahydroimidazo[2,1-b]quinazoline, a New Antihypertensive
Agent. J. Med. Chem. 1973, 16, 407-408.
4. Jen, T.; Dienel B.; Bowman, H.; Petta, J.; Helt, A.; Loev, B. Amidines 2. A New Class of
Antihypertensive Agents. 1,2,3,5-Tetrahydroimidazo[2,1-b]quinazolines. J. Med. Chem. 1972,
15, 727-731.
5.
Sączewski, F.; Kobierska, E.; Petrusewicz, J.; Gendźwiłł, A.; Gdaniec, M. Sythesis and Structure
of Novel 2,3,5,6-Tetrahydro-1H-imidazo[2,1-b][1,3,5]triazepines with Vasocontractile Activity
in Rabbit Aortic Rings. Il Farmaco 2003, 58, 1171-1178.
6.
7.
Orpen, A.G.; L. Brammer, Allen, F.H.; Kennard, O.; Watson, D.G.; Taylor, R. In Structure
Correlation; H.-B. Bürgi, J.D. Dunitz, Eds.; VCH Publishers, Inc.: New York, 1994; 2, 751.
Full geometry optimization, total energy calculations and obtaining the graphs that show the
absolute values of the HOMO/LUMO and absolute values of the electrostatic potential on the

Molecules 2004, 9
100
electron density isosurface corresponding van der Waals contact surface were performed using ab
initio module (6-31G** basis set, direct Hartree-Fock method) as implemented in the SPARTAN
program version 5.0, 1977 (Wavefunction Inc.), installed on a Silicon Graphics O2 workstation.
Kuehne, M.E.; Weaver, S.J.; Franz, P. Enamines as 1,3-Dipolarophiles. J. Org. Chem. 1964, 29,
1582-1585.
8.
9.
Munk, M.E.; Kim, Y.K. Enamines as Dipolarophiles in 1,3-Dipolar Addition Reactions. J. Am.
Chem. Soc. 1964, 86, 2213-2217.
10. Tsuge, O.; Tashiro, M.; Nishihara, Y. Enamine Chemistry I. Dipolar Cycloaddition Reaction of
Enamines with Nitrones. Tetrahedron Lett. 1967, 38, 3769-3774.
11. Nomura, Y.; Furusaki, F.; Takeuchi, Y. 1,3-Dipolar Cycloaddition of Diphenylnitrone to
Enamines. Bull. Chem. Soc. Jpn. 1967, 40, 1740.
12. Nomura, Y.; Furusaki, F.; Takeuchi, Y. “Reverse-oriented” Cycloaddition of Nitrone to
Enamine. Bull. Chem. Soc. Jpn. 1970, 43, 1913.
13. Brannock, K.C.; Burpitt, R.D.; Goodlett, V.W.; Thweatt, J.G. Enamine Chemistry. II. Reactions
with Acetylenedicarboxylates. J. Org. Chem. 1963, 28, 1464-1468.
14. Verboom, W.; Visser G.W.; Trompenaars, W.P.; Reinhoudt, D.N.; Harkema, S.; Van Hummel,
G.J. Sythesis of Pyrrolizines by Intramolecular Capture of 1,4-Dipolar Intermediates in Reactions
of Enamines with Dimethyl Acetylenedicarboxylate. Tetrahedron 1981, 37, 3525-3533.
15. Menachery, M.D.; Saā, J.M.; Cava, M.P. Dehydroaporphines. Enamine-Type Michael Additions.
J. Org. Chem. 1981, 46, 2584-2588.
16. Kozerski, L.; Dąbrowski, J. Conformational Studies by Nuclear Magnetic Resonance –V. 13C
Spectra and Structural Problems of Enamino Carbonyl Compounds. Org. Magn. Reson. 1973, 5,
459-462.
17. Dąbrowski, J.; Kozerski, L. Conformational Studies by Nuclear Magnetic Resonance-VI. C-C
and C-N Rotation Bariers in Various Enamine Derivatives. Org. Magn. Reson. 1973, 5, 469-470.
18. Dąbrowski, J.; Kamieńska-Trela, K.; Kozerski, L. Conformational Studies by Nuclear Magnetic
Resonance. VII-The Direct Observation of Rotational Isomers in some Enamino Carbonyl
Compounds and their Thione Derivatives by Carbon Magnetic Resonance. Org. Magn. Reson.
1974, 6, 499-502.
19. Dąbrowski, J.; K. Kamieńska-Trela, K. Electronic Spectra of α,β-Unsaturated Carbonyl
Compounds. I. An Evaluation of Increments Characteristic of Changes in Configuration (cis /
trans) and Conformation (s-cis / s-trans) Based on Direct Observation of the Isomerization of
Enamino Aldehydes and Ketones. J. Am. Chem. Soc. 1976, 98, 2826-2834.
20. Kozerski, L.; Kamieńska-Trela, K.; Kania, L. 15N-NMR Study of Activated Enamines. Structural
n
Dependence of δ (15N) and J (N, H) in Primary, Secondary and Tertiary Enamino-Ketones,
Esters and Amides. Helv. Chim. Acta 1983, 66, 2113-2128.
21. Vdovenko, S.I.; Gerus, I.I.; Gorbunova, M.G. J. α,β-Unsaturated Enamino-ketones with
Trifluoromethyl Groups. Infrared Spectra and Structure. J. Chem. Soc. Perkin. Trans. 2 1993,
559-562.

Molecules 2004, 9
101
17
22. Zhuo, J.C. O NMR Spectroscopic Study of Tertiary Enaminones. Magn. Reson. Chem. 1996,
34, 595-602.
23. Bondi, A. Van der Waals Volumes and Radii. J. Phys. Chem. 1964, 68, 441-451.
24. Trani, A.; Bellasio, E. Synthesis of 2-Chloro-2-imidazoline and its Reactivity with Aromatic
Amines, Phenols, and Thiophenols. J. Heterocyl. Chem. 1974, 11, 257-261.
25. Rundel,W. In Houben-Weil, Methoden der Organischen Chemie 1968, 10/4, 311.
26. CCDC 229413 (compound 3) and 229414 (compound 18) contain the supplementary
crystallographic data for these compounds. These data can be obtained free of charge via
www.ccdc.cam.ac.uk/conts/retrieving.html (or from the CCDC, 12 Union Road, Cambridge CB2
1EZ, UK; fax: +44 1223 336033; e-mail: deposit@ccdc.cam.ac.uk).
© 2004 by MDPI (http:www.mdpi.org). Reproduction is permitted for noncommercial purposes.